Recent reports of thrombosis following AstraZeneca COVID-19 vaccine in young females (<55 years-old) led to temporary suspension and urgent investigation by the European Medicines Agency (EMA) that concluded that vaccine benefits still outweigh its side effects (SEs). Therefore, this study aims to provide early independent evidence on the vaccine SEs' prevalence and their potential risk factors; a cross-sectional survey-based study was carried out between February and March 2021 in Germany and Czech Republic among healthcare workers who recently received the AstraZeneca COVID-19 vaccine. The study used a validated self-administered questionnaire composed of twenty-eight multiple-choice items covering demographic variables, medical anamneses, and local, systemic, oral, and skin related SEs of the vaccine. Out of the ninety-two included participants, 77.2% were females and 79.3% were from Germany. Their mean age was 35.37 ± 12.62 (19-64) years-old, 15.2% had chronic illnesses and 22.8% were receiving medical treatments. Overall, 94.6% of the participants reported at least one SE. The most common local SE was injection site pain (72.8%), and the most common systemic SEs were fatigue (73.9%), muscle pain (55.4%), chills (48.9%), feeling unwell (46.7%), nausea (45.7%), and headache (29.3%). The vast majority (91.9%) resolved within 1-3 days, and the below 35 years-old group was the least affected age group. The SEs' frequency was insignificantly higher in females and previously infected participants; the vaccine safety for the elderly was supported by the early findings of this study. Chronic illnesses and medical treatments were not associated with an increased risk of SE incidence and frequency. No blood disorder SEs were reported in our sample. Further independent studies are highly required to evaluate the safety of the AstraZeneca vaccine and to explore whether gender or previous infection could be associated with the vaccine SEs.

Clinic for Conservative Dentistry and Periodontology School of Dental Medicine Christian Albrecht's University 24105 Kiel Germany

Czech Clinical Research Infrastructure Network Department of Pharmacology Faculty of Medicine Masaryk University Kamenice 5 625 00 Brno Czech Republic

Czech National Centre for Evidence Based Healthcare and Knowledge Translation Institute of Biostatistics and Analyses Faculty of Medicine Masaryk University Kamenice 5 625 00 Brno Czech Republic

Department of Nursing and Midwifery Faculty of Medicine Masaryk University Kamenice 5 625 00 Brno Czech Republic

Department of Oral and Maxillofacial Surgery Justus Liebig University Klinikstrasse 33 35392 Giessen Germany

Department of Public Health Faculty of Medicine Masaryk University Kamenice 5 625 00 Brno Czech Republic

Institute of Health Information and Statistics of the Czech Republic Palackého Náměstí 375 4 128 01 Praha Czech Republic

Zobrazit více v PubMed

Attia S., Howaldt H.-P. Impact of COVID-19 on the Dental Community: Part I before Vaccine (BV) J. Clin. Med. 2021;10:288. doi: 10.3390/jcm10020288. PubMed DOI PMC

Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. PubMed DOI PMC

Knoll M.D., Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397:72–74. doi: 10.1016/S0140-6736(20)32623-4. PubMed DOI PMC

Mahase E. How the Oxford-AstraZeneca covid-19 vaccine was made. BMJ. 2021;372:n86. doi: 10.1136/bmj.n86. PubMed DOI

Emary K.R.W., Golubchik T., Aley P.K., Ariani C.V., Angus B.J., Bibi S. Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC202012/01 (B.1.1.7) SSRN J. 2021;397:1351–1362. doi: 10.2139/ssrn.3779160. PubMed DOI PMC

European Medicines Agency (EMA) EMA Recommends COVID-19 Vaccine AstraZeneca for Authorisation in the EU. [(accessed on 20 March 2021)]; Available online: https://www.ema.europa.eu/en/news/ema-recommends-covid-19-vaccine-astrazeneca-authorisation-eu.

European Medicines Agency (EMA) COVID-19 Vaccine AstraZeneca. [(accessed on 20 March 2021)]; Available online: https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-astrazeneca.

Heggie H. COVID-19 Vaccine Protocol (CVAP) (ChAdOx1-S) Solution for Injection COVID-19 Vaccine AstraZeneca. Deparment of Health; Hong Kong, China: 2021.

CHMP . COVID-19 Vaccine AstraZeneca, COVID 19 Vaccine (ChAdOx1 S [Recombinant]) CHMP; London, UK: 2021.

Hocková B., Riad A., Valky J., Šulajová Z., Stebel A., Slávik R., Bečková Z., Pokorná A., Klugarová J., Klugar M. Oral Complications of ICU Patients with COVID-19: Case-Series and Review of Two Hundred Ten Cases. J. Clin. Med. 2021;10:581. doi: 10.3390/jcm10040581. PubMed DOI PMC

Riad A., Klugar M., Krsek M. COVID-19-Related Oral Manifestations: Early Disease Features? Oral Dis. 2020;30 doi: 10.1111/odi.13516. PubMed DOI PMC

Riad A., Kassem I., Stanek J., Badrah M., Klugarova J., Klugar M. Aphthous stomatitis in COVID-19 patients: Case-series and literature review. Dermatol. Ther. 2021;34:e14735. doi: 10.1111/dth.14735. PubMed DOI PMC

Riad A., Kassem I., Issa J., Badrah M., Klugar M. Angular cheilitis of COVID-19 patients: A case-series and literature review. Oral Dis. 2020;23 doi: 10.1111/odi.13675. PubMed DOI PMC

Riad A., Gomaa E., Hockova B., Klugar M. Oral candidiasis of COVID-19 patients: Case report and review of evidence. J. Cosmet. Dermatol. 2021;20:1580–1584. doi: 10.1111/jocd.14066. PubMed DOI PMC

Riad A., Kassem I., Hockova B., Badrah M., Klugar M. Halitosis in COVID-19 patients. Spéc. Care Dent. 2021;41:282–285. doi: 10.1111/scd.12547. PubMed DOI PMC

Badrah M., Riad A., Kassem I., Boccuzzi M., Klugar M. Craniofacial pain in COVID-19 patients with diabetes mellitus: Clinical and laboratory description of 21 cases. J. Med. Virol. 2021;93:2616–2619. doi: 10.1002/jmv.26866. PubMed DOI PMC

Wollina U., Karadağ A.S., Rowland-Payne C., Chiriac A., Lotti T. Cutaneous signs in COVID-19 patients: A review. Dermatol. Ther. 2020;33 doi: 10.1111/dth.13549. PubMed DOI PMC

Sawires L. Effects of the Influenza Vaccine on the Oral Cavity. [(accessed on 16 December 2020)]; Available online: https://stars.library.ucf.edu/cgi/viewcontent.cgi?article=1306&context=honorstheses.

Tarakji B., Ashok N., Alakeel R., Azzeghaibi S., Umair A., Darwish S., Mahmoud R., ElKhatat E. Hepatitis B Vaccination and Associated Oral Manifestations: A Non-Systematic Review of Literature and Case Reports. Ann. Med. Health Sci. Res. 2014;4:829–836. doi: 10.4103/2141-9248.144870. PubMed DOI PMC

Mahase E. Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency. BMJ. 2021;372:n774. doi: 10.1136/bmj.n774. PubMed DOI

Wise J. Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots. BMJ. 2021;372:n699. doi: 10.1136/bmj.n699. PubMed DOI

Mahase E. Covid-19: WHO says rollout of AstraZeneca vaccine should continue, as Europe divides over safety. BMJ. 2021;372:n728. doi: 10.1136/bmj.n728. PubMed DOI

European Medicines Agency (EMA) COVID-19 Vaccine AstraZeneca: Benefits Still Outweigh the Risks Despite Possible Link to Rare Blood Clots with Low Blood Platelets. [(accessed on 20 March 2021)]; Available online: https://www.ema.europa.eu/en/news/covid-19-vaccine-astrazeneca-benefits-still-outweigh-risks-despite-possible-link-rare-blood-clots.

KoBoToolbox Harvard Humanitarian Initiative. [(accessed on 15 August 2020)]; Available online: https://support.kobotoolbox.org/welcome.html.

Masaryk University Oral Side Effects of COVID-19 Vaccine (OSECV) [(accessed on 24 February 2021)]; Available online: https://clinicaltrials.gov/ct2/show/NCT04706156.

Von Elm E., Altman D.G., Egger M., Pocock S.J., Gøtzsche P.C., Vandenbroucke J.P. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies. Br. Med. J. 2007;335:806–808. doi: 10.1136/bmj.39335.541782.AD. PubMed DOI PMC

CZECRIN Czech Clinical Research Infrastructure Network. [(accessed on 2 March 2021)]; Available online: https://czecrin.cz/en/home/

Ústav Zdravotnických Informací a Statistiky České Republiky (ÚZIS ČR) Systém Hlášení Nežádoucích Událostí (SHNU) [(accessed on 8 March 2021)]; Available online: https://shnu.uzis.cz/

Centres for Diseases Control and Prevention (CDC) Reactions and Adverse Events of the Pfizer-BioNTech COVID-19 Vaccine. [(accessed on 7 March 2021)]; Available online: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html.

Riad A., Pokorná A., Attia S., Klugarová J., Koščík M., Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J. Clin. Med. 2021;10:1428. doi: 10.3390/jcm10071428. PubMed DOI PMC

Riad A., Sağıroğlu D., Üstün B., Attia S., Klugar M. Prevalence and Risk Factors of CoronaVac Side Effects: An Independent Cross-Sectional Study among Healthcare Workers in Turkey. J. Clin. Med. 2021;10:2629. doi: 10.3390/jcm10122629. PubMed DOI PMC

Proton Technologies AG General Data Protection Regulation (GDPR) Compliance Guidelines. HORIZON 2020-Project REP-791727-1. [(accessed on 1 May 2020)]; Available online: https://gdpr.eu/

SPSS Inc. IBM SPSS Statistics 27. [(accessed on 14 March 2021)]; Available online: https://www.ibm.com/support/pages/node/3006603.

DeRoo S.S., Pudalov N.J., Fu L.Y. Planning for a COVID-19 Vaccination Program. JAMA. 2020;323:2458. doi: 10.1001/jama.2020.8711. PubMed DOI

Frederiksen L.S.F., Zhang Y., Foged C., Thakur A. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Front. Immunol. 2020;11:1817. doi: 10.3389/fimmu.2020.01817. PubMed DOI PMC

Mekhemar M., Attia S., Dörfer C., Conrad J. The Psychological Impact of the COVID-19 Pandemic on Dentists in Germany. J. Clin. Med. 2021;10:1008. doi: 10.3390/jcm10051008. PubMed DOI PMC

Ammar N., Aly N.M., Folayan M.O., Khader Y., Virtanen J.I., Al-Batayneh O.B., Mohebbi S.Z., Attia S., Howaldt H.-P., Boettger S., et al. Behavior change due to COVID-19 among dental academics—The theory of planned behavior: Stresses, worries, training, and pandemic severity. PLoS ONE. 2020;15:e0239961. doi: 10.1371/journal.pone.0239961. PubMed DOI PMC

Ammar N., Aly N., Folayan M., Khader Y., Mohebbi S., Attia S., Howaldt H.-P., Boettger S., Virtanen J., Madi M., et al. Perceived Preparedness of Dental Academic Institutions to Cope with the COVID-19 Pandemic: A Multi-Country Survey. Int. J. Environ. Res. Public Health. 2021;18:1445. doi: 10.3390/ijerph18041445. PubMed DOI PMC

Habersaat K.B., Jackson C. Understanding vaccine acceptance and demand—and ways to increase them. Bundesgesundheitsblatt-Gesundh. -Gesundh. 2019;63:32–39. doi: 10.1007/s00103-019-03063-0. PubMed DOI PMC

Murphy J., Vallières F., Bentall R.P., Shevlin M., McBride O., Hartman T.K., McKay R., Bennett K., Mason L., Gibson-Miller J., et al. Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom. Nat. Commun. 2021;12:1–15. doi: 10.1038/s41467-020-20226-9. PubMed DOI PMC

Neumann-Böhme S., Varghese N.E., Sabat I., Barros P.P., Brouwer W., Van Exel J., Schreyögg J., Stargardt T. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur. J. Health Econ. 2020;21:977–982. doi: 10.1007/s10198-020-01208-6. PubMed DOI PMC

Hung I.F.N., Poland G.A. Single-dose Oxford–AstraZeneca COVID-19 vaccine followed by a 12-week booster. Lancet. 2021;397:854–855. doi: 10.1016/S0140-6736(21)00528-6. PubMed DOI PMC

Regulatory Approval of COVID-19 Vaccine AstraZeneca-GOV.UK. [(accessed on 22 March 2021)]; Available online: https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca.

Boytchev H. Covid-19: Germany struggles with slow uptake of Oxford AstraZeneca vaccine. BMJ. 2021;372:n619. doi: 10.1136/bmj.n619. PubMed DOI

AstraZeneca Impfung: Universitätsmedizin Greifswald. [(accessed on 22 March 2021)]; Available online: https://www.medizin.uni-greifswald.de/de/ueber-die-umg/aktuelles/astrazeneca-impfung/

Greinacher A., Thiele T., Warkentin T.E., Weisser K., Kyrle P.A., Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. N. Engl. J. Med. 2021;384:2092–2101. doi: 10.1056/NEJMoa2104840. PubMed DOI PMC

Jęśkowiak I., Wiatrak B., Grosman-Dziewiszek P., Szeląg A. The Incidence and Severity of Post-Vaccination Reactions after Vaccination against COVID-19. Vaccines. 2021;9:502. doi: 10.3390/vaccines9050502. PubMed DOI PMC

Side Effects of COVID-19 Inactivated Virus vs. Adenoviral Vector Vaccines: Experience of Algerian Healthcare Workers

Prevalence and Drivers of COVID-19 Vaccine Booster Hesitancy Among German University Students and Employees

COVID-19 Vaccine Acceptance of Pregnant and Lactating Women (PLW) in Czechia: An Analytical Cross-Sectional Study

COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study

The Impact of Information Sources on COVID-19-Related Knowledge, Attitudes, and Practices (KAP) among University Students: A Nationwide Cross-Sectional Study

Self-Reported Adverse Events of COVID-19 Vaccines in Polish Healthcare Workers and Medical Students. Cross-Sectional Study and Pooled Analysis of CoVaST Project Results in Central Europe

Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18-30 Years Old): An Independent Post-Marketing Study

Universal Predictors of Dental Students' Attitudes towards COVID-19 Vaccination: Machine Learning-Based Approach

Side Effects of mRNA-Based COVID-19 Vaccine: Nationwide Phase IV Study among Healthcare Workers in Slovakia

Predictors of Willingness to Receive COVID-19 Vaccine: Cross-Sectional Study of Palestinian Dental Students

Prevalence and Drivers of COVID-19 Vaccine Hesitancy among Czech University Students: National Cross-Sectional Study

Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers